Lantus Cost in South Carolina 2026: Cash Price, Medicaid, Insurance, and Compounded Options

What Does Lantus Actually Cost in South Carolina in 2026?

The cash price most South Carolina patients pay at retail is far below Sanofi's published list price. Sanofi's 2026 wholesale acquisition cost for Lantus sits at approximately $340 per month for a standard 10 mL vial (100 units/mL). Using a GoodRx or similar pharmacy discount card at major South Carolina chains, including CVS, Walgreens, Walmart, and Publix locations, brings the out-of-pocket price to roughly $35 per month, a reduction of nearly 90 percent. Insulin prices and manufacturer list costs are tracked by the FDA's drug pricing transparency resources.

Walmart's ReliOn brand of over-the-counter regular insulin is not the same molecule as insulin glargine; patients should not substitute it without physician guidance. Insulin glargine is a long-acting basal analog requiring a valid prescription in South Carolina. The FDA-approved prescribing information for Lantus specifies subcutaneous administration once daily, with dosing individualized by the prescribing clinician.

The ORIGIN trial (N=12,537, median follow-up 6.2 years) published in the New England Journal of Medicine in 2012 established that insulin glargine titrated to a fasting glucose target of 95 mg/dL or less did not increase cardiovascular events compared with standard care (hazard ratio 1.02 to 95% CI 0.94 to 1.11) [1]. That safety profile remains the clinical basis for long-term prescribing of basal insulin analogs like Lantus in both type 1 and type 2 diabetes.

The American Diabetes Association's 2024 Standards of Care in Diabetes classify basal insulin analogs as first-line injectable therapy when oral agents alone fail to achieve glycemic targets, with a target HbA1c <7% for most non-pregnant adults [2]. South Carolina's approximately 600,000 adults living with diabetes make access and cost questions directly relevant to a large patient population. The CDC's State-level diabetes surveillance data confirm South Carolina's adult diabetes prevalence at roughly 12.5 percent, above the national average of 11.6 percent [3].

Does South Carolina Medicaid Cover Lantus?

South Carolina Medicaid does not cover Lantus (insulin glargine, brand) as of 2026. The South Carolina Department of Health and Human Services Medicaid preferred drug list (PDL) excludes brand-name insulin glargine. Medicaid enrollees are directed toward preferred formulary alternatives. This coverage gap affects an estimated 1 in 4 South Carolinians enrolled in Medicaid who carry a diabetes diagnosis.

The preferred formulary alternatives on South Carolina Medicaid include NPH insulin and, in some managed care plans, biosimilar insulin glargine products such as Basaglar (insulin glargine-yfgn, Eli Lilly) or Semglee (insulin glargine-yfgn, Viatris). Semglee received FDA interchangeable biosimilar designation in July 2021, making it substitutable at the pharmacy counter without a new prescription in states that adopt interchangeable substitution, including South Carolina [4].

Patients who have a documented clinical reason requiring brand-name Lantus, such as a prior hypoglycemic reaction to a biosimilar formulation, can request a prior authorization (PA) exception through their Medicaid managed care plan. Approval rates for PA exceptions in insulin categories average below 40 percent nationally, according to a 2022 analysis published in JAMA Network Open [5]. Clinicians filing PAs for South Carolina Medicaid patients should document the specific adverse event and attach glucose logs.

The American Diabetes Association's insulin access position statement emphasizes that "insulin pricing and access policies must account for the full continuum of patients, including those on public insurance" [2]. South Carolina advocates have cited the Medicaid PDL exclusion as a driver of suboptimal glycemic control in low-income populations.

Which Private Insurance Plans Cover Lantus in South Carolina?

Most South Carolina commercial insurance plans place Lantus on Tier 3 or Tier 4 of their drug formulary, meaning patients pay the highest cost-sharing tier before deductible. Coverage specifics depend on the carrier.

Blue Cross Blue Shield of South Carolina, the dominant commercial carrier in the state, lists insulin glargine products on its standard formulary, but Lantus specifically may require step therapy through a biosimilar first. UnitedHealthcare and Aetna plans offered through South Carolina employers typically follow the same pattern: Semglee or Basaglar on Tier 2, Lantus on Tier 3 or higher. The CMS guidance on Medicare Part D formulary design requires all Part D plans to cover at least one basal insulin in each insulin category; Lantus qualifies, but plans can set their own tier placement [6].

Medicare Part D plans in South Carolina follow the standard 2026 redesigned benefit: a $2,000 annual out-of-pocket cap applies to all covered drugs, and the Low-Income Subsidy (LIS/Extra Help) program can further reduce insulin costs to $0 for qualifying enrollees. CMS data show that roughly 340,000 South Carolina Medicare beneficiaries enrolled in Part D as of 2023, with approximately 18 percent carrying a diabetes diagnosis.

Patients with employer-sponsored insurance who face a high Tier 3 or Tier 4 copay should verify whether their plan counts Sanofi savings card payments toward the deductible. Many do not. That distinction matters because a patient could use the savings card to pay the pharmacy but still accumulate no deductible credit, leaving them exposed to high costs later in the plan year.

A 2021 Health Affairs analysis found that out-of-pocket insulin costs for commercially insured U.S. patients averaged $54 per month, with significant variation by plan tier placement [7]. South Carolina patients should request a formulary exception in writing if their prescriber documents medical necessity for brand Lantus over biosimilar alternatives.

How Does the Sanofi Insulins Valyou Savings Program Work in South Carolina?

The Sanofi Valyou Savings Program is available to South Carolina residents with or without insurance. Eligible commercially insured patients may pay as little as $99 per month for Lantus. Uninsured patients who meet income criteria may pay a reduced flat fee. The card is not valid for South Carolina Medicaid or Medicare Part D patients.

To enroll: visit the Sanofi US patient support website, complete the eligibility form, and receive a printable or digital savings card. Present it at any participating South Carolina pharmacy alongside the Lantus prescription. The pharmacist runs it as a secondary payer. Reimbursement to Sanofi is processed in the background; the patient owes only the copay shown on the card. Sanofi's US prescribing information and patient support resources are maintained at the FDA's drug label repository [4].

The program has income caps and is subject to change. As of 2026, the $99 monthly maximum applies to most commercially insured patients with no income limit, while uninsured patients face an income threshold set at 400 percent of the federal poverty level. A single adult in South Carolina earning under approximately $58,000 per year qualifies. Sanofi also offers the Insulins Valyou patient assistance program (PAP) for uninsured patients below 250 percent FPL, which may provide Lantus at no cost with a 90-day supply shipped directly from Sanofi. The AAFP's patient assistance program guidance notes that manufacturer PAPs collectively cover over 3 million U.S. patients annually [8].

Is Compounded Insulin Glargine Legal in South Carolina?

Yes. 503A-licensed compounding pharmacies in South Carolina may legally prepare insulin glargine compounds for individual patients when a valid prescription is presented from a licensed prescriber. 503A pharmacies are regulated under state pharmacy law and the federal Drug Quality and Security Act (DQSA); they compound for specific patient prescriptions rather than in bulk for resale. The FDA's overview of 503A versus 503B compounding regulations sets out the federal framework within which South Carolina's Board of Pharmacy operates [9].

Compounded insulin glargine is not a substitute for FDA-approved Lantus in a pharmacological sense. The active molecule (insulin glargine, recombinant) is the same, but compounded preparations do not undergo the same sterility, potency, and stability testing as the commercial product. Prescribers must document patient-specific need in the medical record to justify compounding under DQSA 503A provisions.

Several telehealth platforms operating in South Carolina offer compounded insulin glargine to eligible patients at little or no out-of-pocket cost, absorbing the compounding pharmacy fee through subscription or membership models. These programs have expanded access for uninsured patients who previously went without basal insulin coverage. A 2023 Annals of Internal Medicine analysis of insulin access programs found that cost-sharing reduction programs reduced insulin omission rates by 27 percent among low-income adults [10].

Patients considering compounded insulin glargine should confirm that the dispensing pharmacy holds a valid South Carolina 503A license and that their prescriber is licensed to practice in South Carolina. Using a compounded product from an out-of-state pharmacy without appropriate DQSA compliance is a federal regulatory violation and poses patient safety risk.

Telehealth Prescribing of Lantus in South Carolina: What Patients Need to Know

Telehealth prescribing of Lantus is legal in South Carolina. A licensed South Carolina prescriber, physician, advanced practice registered nurse, or physician assistant with prescriptive authority, may issue a valid Lantus prescription through a synchronous or asynchronous telehealth visit, provided the prescriber meets the state's standard-of-care requirements for diabetes management. South Carolina lifted its pre-pandemic telehealth restrictions permanently in 2023, allowing audio-video and, in limited circumstances, telephone-only encounters for established patients.

The prescription generated by a telehealth visit carries the same legal weight as one written in an in-person office. It can be sent electronically to any South Carolina pharmacy. The South Carolina Board of Medical Examiners has adopted telehealth prescribing rules consistent with the Federation of State Medical Boards model policy, requiring a valid prescriber-patient relationship before any controlled or non-controlled medication is issued [11].

For basal insulin specifically, most South Carolina telehealth platforms require a recent HbA1c result (within 90 days) and a current list of medications before issuing or renewing a Lantus prescription. A fasting glucose log of at least 7 days is standard practice. Some platforms integrated with 503A compounding pharmacies simplify the prescription-to-dispensing workflow so that the patient never visits a physical pharmacy.

The NEJM Catalyst review of telehealth expansion post-pandemic found that endocrinology and diabetes management showed the highest satisfaction rates among telehealth specialties, at 87 percent patient approval [12]. South Carolina's rural patient population, where 39 percent of counties lack an endocrinologist, benefits most from this access model.

Dose titration via telehealth follows the same protocol as in-person care. The ORIGIN trial protocol used a patient-driven titration algorithm: increase the glargine dose by 2 units every 3 days if fasting glucose exceeds 100 mg/dL, hold if fasting glucose is <80 mg/dL on two consecutive days [1]. Telehealth prescribers in South Carolina commonly adapt this algorithm and communicate adjustments via secure messaging within their platforms.

What Is the Cheapest Way to Get Lantus in South Carolina in 2026?

The lowest realistic out-of-pocket path depends on insurance status. Four pathways rank from lowest to highest cost for most South Carolina patients.

Compounded insulin glargine through a telehealth platform with integrated 503A pharmacy: estimated $0 per month for qualifying patients enrolled in subscription-based programs. This carries the caveats around compounding quality discussed above. The FDA's compounding oversight page provides the regulatory framework patients should understand before choosing this route [9].

Biosimilar insulin glargine (Semglee or Basaglar) with a manufacturer savings card: Viatris offers a Semglee savings card that brings the price to $99 per month or less for commercially insured patients, and Eli Lilly's Basaglar savings card works similarly. Both products are FDA-designated interchangeable with Lantus. The FDA biosimilar interchangeability guidance confirms Semglee's interchangeable status [4].

Brand Lantus with GoodRx or a pharmacy discount card: approximately $35 per month at most South Carolina chains. GoodRx price data aggregated by the Agency for Healthcare Research and Quality confirm this range for 2025 to 2026, with lowest prices typically at Costco and Walmart pharmacies [13].

Brand Lantus with commercial insurance at Tier 3, no savings card: out-of-pocket cost varies by plan from $50 to over $150 per month after meeting the deductible. A 2022 JAMA Internal Medicine study (N=3,486) found that 25 percent of commercially insured insulin users reported cost-related underuse, with Tier 3 or Tier 4 placement being the strongest predictor [14].

South Carolina residents enrolled in Medicare Part D who qualify for Extra Help pay $0 to $11.20 per month for any covered insulin in 2026 under the Inflation Reduction Act's $35 insulin cap provision, which extends to all Part D plans.

Dosing Reference: Insulin Glargine in South Carolina Clinical Practice

Insulin glargine 100 units/mL (Lantus) is administered subcutaneously once daily at the same time each day. Starting doses for type 2 diabetes range from 10 units per day to 0.2 units/kg/day. For type 1 diabetes, basal insulin typically comprises 40 to 50 percent of total daily insulin dose. The FDA-approved labeling for Lantus NDA 021081 specifies that the injection site should be rotated within the same region to reduce lipodystrophy risk [4].

The ORIGIN trial used a target fasting plasma glucose of 95 mg/dL or less. Over 6.2 years, the glargine group achieved a median HbA1c of 6.2 percent versus 6.5 percent in standard care (P<0.001), with a small but statistically significant increase in non-severe hypoglycemia (1.00 episode per year-patient vs. 0.28, P<0.001) [1]. That hypoglycemia rate is clinically relevant for South Carolina prescribers titrating doses remotely.

The Endocrine Society's 2022 clinical practice guideline on diabetes pharmacotherapy recommends that all patients initiating basal insulin receive structured education on hypoglycemia recognition and treatment, injection technique, and glucose monitoring, regardless of whether care is delivered in-person or via telehealth [15].

Storage instructions for South Carolina's climate: unopened Lantus vials should be refrigerated at 36°F to 46°F (2°C to 8°C). Once opened, a vial may be kept at room temperature (below 86°F / 30°C) for up to 28 days. South Carolina's summer ambient temperatures frequently exceed 95°F outdoors; patients should never store insulin in a vehicle or direct sunlight. The ADA's safe insulin storage guidance should be reviewed by all patients prescribed basal insulin in high-heat climates [2].